Millendo Therapeutics – Consensus Indicates Potential 77.8% Upside

Broker Ratings

Millendo Therapeutics with ticker code (MLND) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 5 and 2 calculating the average target price we see 4. Now with the previous closing price of 2.25 this is indicating there is a potential upside of 77.8%. The day 50 moving average is 1.79 and the 200 moving average now moves to 1.79. The market capitalisation for the company is $43m. Find out more information at: http://www.millendo.com

Millendo Therapeutics, a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index